Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Stock Forecast

IOVA's stock price has decreased by -76.1% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 8 analysts with 12-month price forecasts for Iovance Biotherapeutics stock have an average target of 20.25, with a low estimate of 6.00 and a high estimate of 32. The average target predicts an increase of 472.02% from the current stock price of 3.54.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$6.00	$20.25	$20	$32
Change	+69.49%	+472.02%	+464.96%	+803.93%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	5	5	5	5	4	5
Buy	3	3	3	3	4	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	9	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Asthika Goonewardene Truist Securities	Truist Securities	Strong Buy Maintains $25 → $15	Strong Buy	Maintains	$25 → $15	+323.72%	Mar 3, 2025
Andrea Tan Goldman Sachs	Goldman Sachs	Strong Buy Maintains $22 → $19	Strong Buy	Maintains	$22 → $19	+436.71%	Mar 3, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $34 → $30	Strong Buy	Maintains	$34 → $30	+747.43%	Mar 3, 2025
Michael Ulz Baird	Baird	Buy Maintains $24 → $20	Buy	Maintains	$24 → $20	+464.96%	Feb 28, 2025
Joseph Catanzaro Piper Sandler	Piper Sandler	Hold Maintains $7.5 → $6	Hold	Maintains	$7.5 → $6	+69.49%	Feb 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

460.23M

Increased by 180.51%

from 164.07M

Revenue Next Year

735.50M

Increased by 59.81%

from 460.23M

EPS This Year

-0.89

from -1.28

EPS Next Year

-0.35

from -0.89

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	1.19M	164.07M	460.23M	735.50M	884.01M
Revenue Growth	-	-	-	-	13,698.99%	180.51%	59.81%	20.19%
EPS	-1.88	-2.23	-2.49	-1.89	-1.28	-0.89	-0.35	0.48
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	7.32
No. Analysts	-	-	-	-	-	16	14	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	499.0M	972.4M	1.3B
Avg	460.2M	735.5M	884.0M
Low	395.3M	481.0M	447.7M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	204.1%	111.3%	72.3%
Avg	180.5%	59.8%	20.2%
Low	140.9%	4.5%	-39.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.51	0.16	1.01
Avg	-0.89	-0.35	0.48
Low	-1.25	-0.86	0.08

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.